New treatments for denervating diseases

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There has been considerable recent progress in understanding mechanisms by which gene mutations cause degeneration of motoneurons and peripheral nerves. Novel therapies inspired by these insights have begun to yield promising results in mouse models of these genetic diseases. Among these have been the use of small molecules or proteins to suppress gain-of-function mutations (eg, ascorbic acid for Charcot-Marie-Tooth disease type 1A) or to restore enzyme activities that are deficient because of loss-of-function mutations (eg, treatment of Fabry's disease with recombinant α-galactosidase or with low-molecular-weight α-galactosidase chaperones and treatment of spinal muscular atrophy with phenylbutyrate). Some of these therapies are already being tested in humans. Equally exciting is the prospect that small molecules and proteins will be identified that exert potent therapeutic effects in a broad spectrum of inherited and acquired motoneuron and peripheral nerve disorders.

Original languageEnglish (US)
Pages (from-to)258-262
Number of pages5
JournalJournal of Child Neurology
Volume20
Issue number3
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Galactosidases
Motor Neurons
Peripheral Nerves
Mutation
Phenylbutyrates
Charcot-Marie-Tooth Disease
Fabry Disease
Spinal Muscular Atrophy
Inborn Genetic Diseases
Therapeutic Uses
Ascorbic Acid
Proteins
Molecular Weight
Enzymes
Therapeutics
Genes

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

New treatments for denervating diseases. / Pleasure, David E.

In: Journal of Child Neurology, Vol. 20, No. 3, 03.2005, p. 258-262.

Research output: Contribution to journalArticle

@article{ce31e83d45114d8eb7d55c2df5d9fe4e,
title = "New treatments for denervating diseases",
abstract = "There has been considerable recent progress in understanding mechanisms by which gene mutations cause degeneration of motoneurons and peripheral nerves. Novel therapies inspired by these insights have begun to yield promising results in mouse models of these genetic diseases. Among these have been the use of small molecules or proteins to suppress gain-of-function mutations (eg, ascorbic acid for Charcot-Marie-Tooth disease type 1A) or to restore enzyme activities that are deficient because of loss-of-function mutations (eg, treatment of Fabry's disease with recombinant α-galactosidase or with low-molecular-weight α-galactosidase chaperones and treatment of spinal muscular atrophy with phenylbutyrate). Some of these therapies are already being tested in humans. Equally exciting is the prospect that small molecules and proteins will be identified that exert potent therapeutic effects in a broad spectrum of inherited and acquired motoneuron and peripheral nerve disorders.",
author = "Pleasure, {David E}",
year = "2005",
month = "3",
language = "English (US)",
volume = "20",
pages = "258--262",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - New treatments for denervating diseases

AU - Pleasure, David E

PY - 2005/3

Y1 - 2005/3

N2 - There has been considerable recent progress in understanding mechanisms by which gene mutations cause degeneration of motoneurons and peripheral nerves. Novel therapies inspired by these insights have begun to yield promising results in mouse models of these genetic diseases. Among these have been the use of small molecules or proteins to suppress gain-of-function mutations (eg, ascorbic acid for Charcot-Marie-Tooth disease type 1A) or to restore enzyme activities that are deficient because of loss-of-function mutations (eg, treatment of Fabry's disease with recombinant α-galactosidase or with low-molecular-weight α-galactosidase chaperones and treatment of spinal muscular atrophy with phenylbutyrate). Some of these therapies are already being tested in humans. Equally exciting is the prospect that small molecules and proteins will be identified that exert potent therapeutic effects in a broad spectrum of inherited and acquired motoneuron and peripheral nerve disorders.

AB - There has been considerable recent progress in understanding mechanisms by which gene mutations cause degeneration of motoneurons and peripheral nerves. Novel therapies inspired by these insights have begun to yield promising results in mouse models of these genetic diseases. Among these have been the use of small molecules or proteins to suppress gain-of-function mutations (eg, ascorbic acid for Charcot-Marie-Tooth disease type 1A) or to restore enzyme activities that are deficient because of loss-of-function mutations (eg, treatment of Fabry's disease with recombinant α-galactosidase or with low-molecular-weight α-galactosidase chaperones and treatment of spinal muscular atrophy with phenylbutyrate). Some of these therapies are already being tested in humans. Equally exciting is the prospect that small molecules and proteins will be identified that exert potent therapeutic effects in a broad spectrum of inherited and acquired motoneuron and peripheral nerve disorders.

UR - http://www.scopus.com/inward/record.url?scp=17644381943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644381943&partnerID=8YFLogxK

M3 - Article

C2 - 15832625

AN - SCOPUS:17644381943

VL - 20

SP - 258

EP - 262

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 3

ER -